PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
- Mechanism
- Curator reviewed
It has been shown that Hepatitis B surface (HBsAg) and core antigen (HBcAg) induces envelope-and core specific CD4+ and CD8+ T-cell responses and that the response against the Hepatitis B core antigen (HBcAg), is often associated with viral control. The combination of these two genes in PowderMed's pdpSC18 HBV therapeutic DNA vaccine, thus provides a potential mechanism to both clear the virus via the CD8+ response and to overcome unresponsiveness in chronically infected patients via the CD4+ response.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
- Code names
- PDPSC18
Which companies are running trials of PDPSC18, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account